litlas
Log inCreate account

Ursula A. Matulonis

Active 1992–2025

Also published as
Ursula A Matulonis
213
Papers
39,525
Citations
104
h-index
207
i10-index

Citations

Citations per year for Ursula A. Matulonis1945: 1 citations1993: 1 citations1994: 10 citations1995: 13 citations1996: 12 citations1997: 12 citations1998: 10 citations1999: 8 citations2000: 8 citations2001: 10 citations2002: 27 citations2003: 39 citations2004: 41 citations2005: 28 citations2006: 34 citations2007: 34 citations2008: 64 citations2009: 58 citations2010: 101 citations2011: 167 citations2012: 173 citations2013: 235 citations2014: 273 citations2015: 295 citations2016: 413 citations2017: 485 citations2018: 486 citations2019: 1,659 citations2020: 2,077 citations2021: 2,118 citations2022: 1,799 citations2023: 1,500 citations2024: 2,100 citations2025: 1,022 citations2026: 18 citations1946–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,610 citing papers, 27.8% of this breakdownChina: 2,100 citing papers, 12.6% of this breakdownUnited Kingdom: 1,128 citing papers, 6.8% of this breakdownItaly: 837 citing papers, 5% of this breakdownCanada: 688 citing papers, 4.1% of this breakdownGermany: 641 citing papers, 3.9% of this breakdownFrance: 613 citing papers, 3.7% of this breakdownSpain: 538 citing papers, 3.2% of this breakdownAustralia: 479 citing papers, 2.9% of this breakdownJapan: 449 citing papers, 2.7% of this breakdownNetherlands: 396 citing papers, 2.4% of this breakdownSwitzerland: 303 citing papers, 1.8% of this breakdown
0%27.8%Other 23.1%

Institutions

Fields

  • Medicine61.7%
  • Biochemistry, Genetics and Molecular Biology27.5%
  • Immunology and Microbiology5.9%
  • Materials Science1.1%
  • Engineering0.9%
  • Computer Science0.5%
  • Other2.4%

Topics

  • PARP inhibition in cancer therapy8.1%
  • Ovarian cancer diagnosis and treatment6.8%
  • Cancer Immunotherapy and Biomarkers3.8%
  • DNA Repair Mechanisms3.7%
  • Cancer Genomics and Diagnostics2.8%
  • Endometrial and Cervical Cancer Treatments2.2%
  • Other72.6%

Coauthors

All papers

Open in search
  1. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Authors: Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, Noa Ben-Baruch, Christian Marth, Radosław Mądry, René dePont Christensen, Jonathan S. Berek, Anne Dørum, Anna V. Tinker, Andreas du Bois, Antonio González-Martı́n, Philippe Follana, Benedict B. Benigno, Per Rosenberg, Lucy Gilbert, B.J. Rimel, Joseph Buscema, John Balser, Shefali Agarwal, Ursula A. Matulonis - New England Journal of Medicine 2016 cited by 2,458

  2. A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

    Authors: Michal Slyper, Caroline Porter, Orr Ashenberg, Julia Waldman, Eugene Drokhlyansky, Isaac Wakiro, Christopher S. Smillie, Gabriela Smith-Rosario, Jingyi Wu, Danielle Dionne, Sébastien Vigneau, Judit Jané‐Valbuena, Timothy L. Tickle, Sara Napolitano, Mei-Ju Su, Anand G. Patel, Åsa Karlström, Simon Gritsch, Masashi Nomura, Avinash Waghray, Satyen H. Gohil, Alexander M. Tsankov, Livnat Jerby‐Arnon, Ofir Cohen, Johanna Klughammer, Yanay Rosen, Joshua Gould, Lan Nguyễn, Matan Hofree, Peter J. Tramontozzi, Bo Li, Catherine J. Wu, Benjamin Izar, Rizwan Haq, F. Stephen Hodi, Charles H. Yoon, Aaron N. Hata, Suzanne J. Baker, Mario L. Suvà, Raphael Bueno, Elizabeth H. Stover, Michael R. Clay, Michael A. Dyer, Natalie B. Collins, Ursula A. Matulonis, Nikhil Wagle, Bruce E. Johnson, Asaf Rotem, Orit Rozenblatt–Rosen, Aviv Regev - Nature Medicine 2020 cited by 805

  3. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

    Authors: Ursula A. Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Andrew Dean, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo, Philipp Harter, Conleth G. Murphy, Jiuzhou Wang, Elizabeth Noble, Brooke Esteves, Michael Method, Robert L. Coleman - Journal of Clinical Oncology 2023 cited by 372

  4. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    Authors: Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin, Alla Lisyanskaya, Sandro Pignata, Ignace Vergote, Francesco Raspagliesi, Gabe S. Sonke, Michael J. Birrer, Diane Provencher, Jalid Sehouli, Nicoletta Colombo, Antonio González-Martı́n, Ana Oaknin, Petronella B. Ottevanger, Vilius Rudaitis, Kianoosh Katchar, Huita Wu, Stephen J. O’Keefe, Jane Ruman, Jonathan A. Ledermann - Annals of Oncology 2019 cited by 840

  5. Ovarian cancer

    Authors: Ursula A. Matulonis, Anil K. Sood, Lesley Fallowfield, Brooke E. Howitt, Jalid Sehouli, Beth Y. Karlan - Nature Reviews Disease Primers 2016 cited by 1,291

  6. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

    Authors: Qiwei Wang, Johann S. Bergholz, Liya Ding, Ziying Lin, Sheheryar Kabraji, Melissa E. Hughes, Xiadi He, Shaozhen Xie, Tao Jiang, Weihua Wang, Jason J. Zoeller, Hye‐Jung Kim, Thomas M. Roberts, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Deborah Dillon, Eric P. Winer, Nancy U. Lin, Jean J. Zhao - Nature Communications 2022 cited by 247

  7. A single-cell landscape of high-grade serous ovarian cancer

    Authors: Benjamin Izar, Itay Tirosh, Elizabeth H. Stover, Isaac Wakiro, Michael S. Cuoco, Idan Alter, Christopher Rodman, Rachel Leeson, Mei-Ju Su, Parin Shah, Marcin Iwanicki, Sarah R. Walker, Abhay Kanodia, Johannes C. Melms, Shaolin Mei, Jia‐Ren Lin, Caroline Porter, Michal Slyper, Julia Waldman, Livnat Jerby‐Arnon, Orr Ashenberg, Titus J. Brinker, Caitlin E. Mills, Meri Rogava, Sébastien Vigneau, Peter K. Sorger, Levi A. Garraway, Panagiotis A. Konstantinopoulos, Joyce F. Liu, Ursula A. Matulonis, Bruce E. Johnson, Orit Rozenblatt–Rosen, Asaf Rotem, Aviv Regev - Nature Medicine 2020 cited by 522

  8. Clinical and translational advances in ovarian cancer therapy

    Authors: Panagiotis A. Konstantinopoulos, Ursula A. Matulonis - Nature Cancer 2023 cited by 361

  9. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

    Authors: Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal, Monica Mita, John W. Moroney, Robert W. Holloway, Linda Van Le, Jasgit C. Sachdev, Eloise Chapman‐Davis, Gerardo Colón‐Otero, Richard T. Penson, Ursula A. Matulonis, Young Bae Kim, Kathleen N. Moore, Elizabeth M. Swisher, Anniina Färkkilä, Alan D. D’Andrea, Erica Stringer-Reasor, Jing Wang, Nathan Buerstatte, Sujata Arora, Julie R. Graham, Dmitri Bobilev, Bruce J. Dezube, Pamela N. Münster - JAMA Oncology 2019 cited by 560

  10. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

    Authors: Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedländer, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Euan Macpherson, Claire Watkins, James Carmichael, Ursula A. Matulonis - New England Journal of Medicine 2012 cited by 1,891

  11. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

    Authors: Liya Ding, Hye‐Jung Kim, Qiwei Wang, Michael Kearns, Tao Jiang, Carolynn E. Ohlson, Ben B. Li, Shaozhen Xie, Joyce F. Liu, Elizabeth H. Stover, Brooke E. Howitt, Roderick T. Bronson, Suzan Lazo, Thomas M. Roberts, Gordon J. Freeman, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Jean J. Zhao - Cell Reports 2018 cited by 571

  12. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Authors: Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedländer, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Anitra Fielding, Stuart Spencer, Brian Dougherty, Maria Orr, Darren Hodgson, J. Carl Barrett, Ursula A. Matulonis - The Lancet Oncology 2014 cited by 1,443

  13. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

    Authors: Sarah J. Hill, Brennan Decker, Emma A. Roberts, Neil S. Horowitz, Michael G. Muto, Michael J. Worley, Colleen M. Feltmate, Marisa R. Nucci, Elizabeth M. Swisher, Huy Nguyen, Chunyu Yang, Ryuji Morizane, Bose Kochupurakkal, T. Khanh, Panagiotis A. Konstantinopoulos, Joyce F. Liu, Joseph V. Bonventre, Ursula A. Matulonis, Geoffrey I. Shapiro, Ross S. Berkowitz, Christopher P. Crum, Alan D. D’Andrea - Cancer Discovery 2018 cited by 457

  14. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

    Authors: M. William Audeh, James Carmichael, Richard T. Penson, Michael Friedländer, Bethan Powell, Katherine M. Bell‐McGuinn, Clare L. Scott, Jeffrey N. Weitzel, Ana Oaknin, Niklas Loman, Karen H. Lu, Rita K. Schmutzler, Ursula A. Matulonis, Mark Wickens, Andrew Tutt - The Lancet 2010 cited by 2,283

  15. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

    Authors: Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller, David S. Miller, Noelle Cloven, Gini F. Fleming, Andrea E. Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M. Oza, Mihaela Cristea, Jonathan S. Berek, John K. Chan, B.J. Rimel, Daniela Matei, Yong Li, Kaiming Sun, Katarina Luptakova, Ursula A. Matulonis, Bradley J. Monk - The Lancet Oncology 2019 cited by 537

  16. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

    Authors: Lucy Gilbert, Ana Oaknin, Ursula A. Matulonis, Gina Mantia-Smaldone, Peter Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Michael Method, Jiuzhou Wang, Kathleen N. Moore, David M. O’Malley - Gynecologic Oncology 2023 cited by 108

  17. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

    Authors: Daniela Matei, Virginia L. Filiaci, Marcus E. Randall, David G. Mutch, Margaret M. Steinhoff, Paul DiSilvestro, Katherine Moxley, Yong M. Kim, Matthew A. Powell, David M. O’Malley, Nick M. Spirtos, William Small, Krishnansu S. Tewari, William E. Richards, John Nakayama, Ursula A. Matulonis, Helen Huang, David S. Miller - New England Journal of Medicine 2019 cited by 467

  18. Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

    Authors: Brooke E. Howitt, Sachet A. Shukla, Lynette M. Sholl, Lauren L. Ritterhouse, Jaclyn C. Watkins, Scott J. Rodig, Elizabeth H. Stover, Kyle C. Strickland, Alan D. D’Andrea, Catherine J. Wu, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos - JAMA Oncology 2015 cited by 685

  19. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

    Authors: Anniina Färkkilä, D. Gulhan, Julia Casado, Connor A. Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu‐An Chen, Denis Schapiro, Yinghui Zhou, Julie R. Graham, Bruce J. Dezube, Pamela N. Münster, Sandro Santagata, Elizabeth Garcia, Scott J. Rodig, Ana Lako, Dipanjan Chowdhury, Geoffrey I. Shapiro, Ursula A. Matulonis, Peter J. Park, Sampsa Hautaniemi, Peter K. Sorger, Elizabeth M. Swisher, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos - Nature Communications 2020 cited by 341

  20. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

    Authors: Panagiotis A. Konstantinopoulos, Su-Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle, Elizabeth K. Lee, Elise C. Kohn, Linda Duska, Marta A. Crispens, Alexander Olawaiye, Ira Winer, Lisa Barroilhet, Siqing Fu, Michael McHale, Russell J. Schilder, Anniina Färkkilä, Dipanjan Chowdhury, Jennifer Curtis, Roxanne Quinn, Brittany Bowes, Alan D. D’Andrea, Geoffrey I. Shapiro, Ursula A. Matulonis - The Lancet Oncology 2020 cited by 232

  21. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer

    Authors: Changxin Wan, Matthew P. Keany, Han Dong, Linah Al-Alem, Unnati M. Pandya, Suzan Lazo, Karsten Boehnke, Katherine N. Lynch, Rui Xu, Dominique T. Zarrella, Shengqing Gu, Paloma Cejas, Klothilda Lim, Henry W. Long, Kevin M. Elias, Neil S. Horowitz, Colleen M. Feltmate, Michael G. Muto, Michael J. Worley, Ross S. Berkowitz, Ursula A. Matulonis, Marisa R. Nucci, Christopher P. Crum, Bo R. Rueda, Myles Brown, Xiaole Shirley Liu, Sarah J. Hill - Cancer Research 2020 cited by 215

  22. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma

    Authors: Joyce F. Liu, Niya Xiong, Susana M. Campos, Alexi A. Wright, Carolyn Krasner, Susan Schumer, Neil S. Horowitz, Jennifer Veneris, Nabihah Tayob, Stephanie Morrissey, Gabriela West, Roxanne Quinn, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos - Journal of Clinical Oncology 2021 cited by 195

  23. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

    Authors: Liya Ding, Qiwei Wang, Antons Martincuks, Michael J. Kearns, Tao Jiang, Ziying Lin, Xin Cheng, Changli Qian, Shaozhen Xie, Hye‐Jung Kim, Inga-Maria Launonen, Anniina Färkkilä, Thomas M. Roberts, Gordon J. Freeman, Joyce F. Liu, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Hua Yu, Jean J Zhao - Journal for ImmunoTherapy of Cancer 2023 cited by 92

  24. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer

    Authors: Joyce F. Liu, Christina I. Herold, Kathryn P. Gray, Richard T. Penson, Neil S. Horowitz, Panagiotis A. Konstantinopoulos, Cesar M. Castro, Sarah J. Hill, Jennifer Curtis, Weixiu Luo, Ursula A. Matulonis, Stephen A. Cannistra, Don S. Dizon - JAMA Oncology 2019 cited by 227